Provided by Tiger Trade Technology Pte. Ltd.

HANSOH PHARMA

34.000
0.000
Volume:6K
Turnover:204.00K
Market Cap:206.18B
PE:31.28
High:34.000
Open:34.000
Low:34.000
Close:34.000
52wk High:43.939
52wk Low:27.882
Shares:6.06B
HK Float Shares:6.06B
Volume Ratio:- -
T/O Rate:0.00%
Dividend:0.43
Dividend Rate:1.27%
EPS(LYR):1.087
ROE:19.40%
ROA:9.08%
PB:4.67
PE(LYR):31.28
PS:11.10

Loading ...

Hansoh Pharmaceutical Group Stock Falls 4.1% in Hong Kong

Dow Jones
·
Jul 17

Movement Alert|Hansoh Pharmaceutical Falls 3.08% in Regular Trading, Broad Pharmaceutical Sector Weakness Drags Shares Lower

Market Focus
·
Jul 17

Movement Alert|Hansoh Pharmaceutical Rises 3.17% in Regular Trading, Multiple Catalysts Including Avere-NextCure Merger and HS-20093 Phase III Success Drive Momentum

Market Focus
·
Jul 16

Hansoh Pharma Earns MSCI ESG AAA Rating

Reuters
·
Jul 15

HANSOH PHARMA Shares Surge on Global Licensing Deal and Merger Announcement

Stock News
·
Jul 15

Movement Alert|Hansoh Pharmaceutical Rises 3.5% in Regular Trading, Subsidiary Avere to Merge into Nasdaq-Listed NextCure

Market Focus
·
Jul 15

Hansoh Pharmaceutical Discloses Transactions with Avere Therapeutics

Reuters
·
Jul 14

Hansoh Pharma Licenses Oral IL-23 Drug Hs-20118 to Avere in Deal Worth up to USD 2.3 Billion

Reuters
·
Jul 14

Hansoh-backed Avere Agrees to Merge with Nextcure in All-stock Deal

Reuters
·
Jul 14

Hansoh Pharmaceutical - Avere Therapeutics to Merge into Nextcure Under Merger Agreement Signed July 14, 2026

THOMSON REUTERS
·
Jul 14

Hansoh Pharmaceutical - Combined Entity to Operate as Avere Therapeutics, and Trade as Avrx

THOMSON REUTERS
·
Jul 14

Hansoh Pharmaceutical - Hanshoh Pharma to Hold over 30% but Under 40% of Combined Entity Post-merger

THOMSON REUTERS
·
Jul 14

Hansoh Pharmaceutical Group Stock Rises 1.8% in Hong Kong

Dow Jones
·
Jul 13

HANSOH PHARMA Shares Surge on Positive Phase III Trial Results for Lung Cancer Drug

Stock News
·
Jul 13

Movement Alert|Hansoh Pharma Rises 3.51% in Regular Trading, Core ADC Drug HS-20093 Achieves OS Primary Endpoint in Phase III SCLC Trial

Market Focus
·
Jul 13

Hong Kong Market Morning Digest: State Council Calls for Systematic Digital China Development; CITIC SEC Forecasts 69.59% H1 Net Profit Surge

Stock News
·
Jul 13

HANSOH PHARMA's Global Expansion Strategy: A Quiet but Steady Ascent

Deep News
·
Jul 12

Hansoh Pharmaceutical Says Hs-20,093 Meets Primary Endpoint in Phase III SCLC Trial

Reuters
·
Jul 10

Hansoh Pharma’s B7-H3 ADC HS-20093 Delivers Statistically Significant Overall-Survival Benefit in Phase III Small Cell Lung Cancer Trial

Bulletin Express
·
Jul 10

Hansoh Pharmaceutical - Hs-20,093 Meets Primary Endpoint in Phase Iii Sclc Trial

THOMSON REUTERS
·
Jul 10